Clinical results of radionuclide therapy of neuroendocrine tumours with (90)Y-DOTATATE and tandem (90)Y/(177)Lu-DOTATATE: which is a better therapy option?

PURPOSE: Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). A combination treatment using the high-energy (90)Y beta emitter for larger lesions and the lower energy (177)Lu for sma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunikowska, Jolanta, Królicki, Leszek, Hubalewska-Dydejczyk, Alicja, Mikołajczak, Renata, Sowa-Staszczak, Anna, Pawlak, Dariusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168754/
https://www.ncbi.nlm.nih.gov/pubmed/21553086
http://dx.doi.org/10.1007/s00259-011-1833-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168754/
https://www.ncbi.nlm.nih.gov/pubmed/21553086
http://dx.doi.org/10.1007/s00259-011-1833-x

Ejemplares similares